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ARTICLE
Membrane association but not identity is required
for LRRK2 activation and phosphorylation of Rab
GTPases
Rachel C. Gomez1, Paulina Wawro1, Pawel Lis2, Dario R. Alessi2, and Suzanne R. Pfeffer1
LRRK2 kinase mutations cause familial Parkinson’s disease and increased phosphorylation of a subset of Rab GTPases. Rab29
recruits LRRK2 to the trans-Golgi and activates it there, yet some of LRRK2’s major Rab substrates are not on the Golgi. We
sought to characterize the cell biology of LRRK2 activation. Unlike other Rab family members, we show that Rab29 binds
nucleotide weakly, is poorly prenylated, and is not bound to GDI in the cytosol; nevertheless, Rab29 only activates LRRK2 when
it is membrane bound and GTP bound. Mitochondrially anchored, GTP-bound Rab29 is both a LRRK2 substrate and activator, and
it drives accumulation of active LRRK2 and phosphorylated Rab10 on mitochondria. Importantly, mitochondrially anchored
LRRK2 is much less capable of phosphorylating plasma membrane–anchored Rab10 than soluble LRRK2. These data support a
model in which LRRK2 associates with and dissociates from distinct membrane compartments to phosphorylate Rab substrates; if
anchored, LRRK2 can modify misdelivered Rab substrates that then become trapped there because GDI cannot retrieve them.
Introduction
Although the majority of Parkinson’s disease cases are idio-
pathic, mutations in the LRRK2 gene are themost common cause
of familial Parkinson’s disease (Simón-Sa´nchez et al., 2009;
Alessi and Sammler, 2018). LRRK2 is a large, 2,527-residue,
multidomain protein kinase that also contains a GTPase “ROC-
COR” domain and other protein scaffolding domains. Pathogenic
mutations in both the ROC-COR and kinase domains increase
LRRK2’s basal kinase activity, which has made LRRK2 an at-
tractive pharmaceutical target. The pathogenic R1441G mutation
in the ROC GTPase domain shows enhanced GTP binding and
increased kinase activity (Lewis et al., 2007; Ito et al., 2016);
these features make it useful for understanding the con-
sequences of LRRK2 phosphorylation on cell physiology that
underlie Parkinson’s disease. WT and R1441G LRRK2 are largely
cytosolic but a pool (∼20%) associates with membranes (Berger
et al., 2010; Purlyte et al., 2018) and colocalizes with Rab8 and
Rab10 GTPases (Purlyte et al., 2018). Membrane-associated
LRRK2 shows a higher level of kinase activity than cytosolic
LRRK2 (Berger et al., 2010; Purlyte et al., 2018), but little is
known about the molecular basis for membrane association or
activation.
Recent phospho-proteomic analyses identified a subset of
Rab GTPases as LRRK2 substrates (Steger et al., 2017), including
Rab8, Rab10, and Rab29. Rab proteins are master regulators of
all membrane trafficking events in eukaryotic cells (Wandinger-
Ness and Zerial, 2014; Pfeffer, 2017). Rabs are membrane an-
chored by stable geranylgeranylation of their C-termini; when
GTP bound, they recruit specific effector proteins to membrane
surfaces to mediate transport vesicle formation, motility, and
target recognition (Pfeffer, 2017). So-called switch regions re-
port the identity of the Rab protein–bound nucleotide; they
change conformation between GTP- and GDP-bound states
(Stroupe and Brunger, 2000; Itzen and Goody, 2011). LRRK2
phosphorylates Rabs on their switch II regions, which interferes
with binding to most of their binding partners, including GDI
(Rab GDP dissociation inhibitor) that mediates Rab membrane
delivery and extraction (Steger et al., 2016; Liu et al., 2018).
Phosphorylated Rab8 and Rab10 (pRab10) proteins also bind
with higher affinity to certain effectors, leading to their reloc-
alization to the mother centriole (Dhekne et al., 2018; Madero-
Pe´rez et al., 2018a).
The Rab29 gene is located within the PARK16 locus linked to
Parkinson’s disease (Simón-Sa´nchez et al., 2009); however, it is
much less clear how mutations in the PARK16 locus influence
Parkinson’s disease. Rab29’s normal function and effector pro-
teins remain elusive, although depletion of Rab29 has been
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suggested to alter Golgi structure, T cell receptor recycling,
mannose 6-phosphate receptor recycling, and cilia formation
(Wang et al., 2014; Onnis et al., 2015). Rab29 and LRRK2 double-
knockout mice exhibit a nonadditive enlarged kidney pheno-
type, implying that these genes act in a common pathway
(Kuwahara et al., 2016). Additionally, in Caenorhabditis elegans,
Rab29 and LRRK2 orthologues function together in a signaling
pathway controlling axon termination (Kuwahara et al., 2016).
Rab29 has recently been shown to activate pathogenic LRRK2
kinase activity and, at least when overexpressed, to recruit
LRRK2 to the Golgi complex (Purlyte et al., 2018). In this study,
we show that Rab29 is an unusual Rab protein in that it binds
nucleotide poorly and is inefficiently prenylated in cells. Nev-
ertheless, GTP binding by Rab29 and membrane association are
required for its ability to trigger LRRK2 activation and substrate
phosphorylation. Surprisingly, the identity of the membrane to
which Rab29 or LRRK2 associates is not important for either of
these processes.
Results
Rab29 has unique biochemical properties
To characterize Rab29-mediated activation of LRRK2, we sought
to understand Rab29’s biochemical properties. Previous work
suggested that Rab29 binds nucleotide more poorly than other
Rab GTPases, based upon its rapid release of prebound, labeled
nucleotides (Delprato et al., 2004; Beilina et al., 2014). In addi-
tion, the Q67L mutant that in other Rabs would be expected to
lock the protein in an active conformation was not localized to
the Golgi and bound nucleotide more weakly than Rab29 WT
protein (Beilina et al., 2014). Additionally, a small pool of T21N
Rab29 localizes to the Golgi (Wang et al., 2014; Madero-Pe´rez
et al., 2018b). This suggested that canonical mutations cannot be
used to study Rab29 and that additional mutagenesis and careful
characterization would be required.
We used fluorescent 29-(39)-bis-O-(N-methylanthraniloyl)-
GDP (MANT-GDP; Delprato et al., 2004) to monitor the disso-
ciation of nucleotide from Rab29 and its mutant derivatives
(Fig. 1, A–E). Purified Rab29 released MANT-GDP twofold faster
than the well-characterized Rab5 GTPase (Fig. 1, A, B, and E).
Upon addition of EDTA to chelate Mg2+, Rab29 released nucle-
otide instantaneously, much quicker than Rab5 protein (com-
pare red and purple lines, Fig. 1, A and B).
Rab29 D63A was created to generate a protein that binds
nucleotide extremely poorly for experiments to test the impor-
tance of Rab29 nucleotide-binding capacity. The D63 residue is
conserved throughout the Ras superfamily and coordinates a
water molecule adjacent to the Mg2+ ion that holds the nucleo-
tide in place. D63 is also involved in GDI binding (Rak et al.,
2003). Although Rab29 D63A could be loaded with similar
amounts of MANT-GDP compared with WT Rab29 (in reactions
containing nucleotide at high concentrations; Fig. 1 D), it re-
leased the bound nucleotide very rapidly (Figs. 1, C and D), and
EDTA had no additional effect, suggesting that this mutant binds
magnesium poorly. Given that Rab29 D63A is entirely cytosolic
upon expression in HEK293T cells (see below), it cannot be
functional.
Cytosolic Rab29 is not GDI bound
Essentially all Rab GTPases studied to date exist in two pools: in
cytosol or membrane bound. When present in cytosol, Rabs are
complexed with GDI, which solubilizes these (mostly) doubly
prenylated Rab GTPases (Araki et al., 1990). Thus, to date, gel
filtration of cytosol has shown that Rabs chromatograph as an
∼80-kD complex with GDI (Soldati et al., 1993), as shown for
Rab9A and Rab8A (Fig. 1 F). Rab29 is ∼35% membrane bound,
which is comparable to other Rab GTPases (Overmeyer et al.,
2001). Unexpectedly, unlike other Rabs, cytosolic Rab29 eluted
after GDI as an ∼25-kD monomer upon S100 gel filtration of
cytosol from HEK293T cells (Fig. 1 F, red line in top panel).
GDI binding depends on Rab GTPase prenylation; thus, it is
possible that Rab29 fails to bind GDI in the cytosol because it is
less efficiently prenylated compared with other Rab proteins.
We compared the abilities of GFP-Rab29 or GFP-Rab10 to be
prenylated in vitro using HEK293T cytosol and a biotinylated
geranyl pyrophosphate precursor (Nguyen et al., 2009). As
shown in Fig. 1 G, in vitro Rab29 prenylation was not detected
under conditions in which Rab10 prenylation was readily ob-
served. Although prenylation of endogenous Rab29 likely occurs
in cells, Rab29’s weak nucleotide binding and inefficient pre-
nylation could lead to decreased GDI binding, possibly explain-
ing the pool of monomeric Rab29 in the cytosol.
Rab prenylation is needed for LRRK2 activation and
substrate phosphorylation
At least 80% of LRRK2 is in the cytosol (Biskup et al., 2006;
Berger et al., 2010; Purlyte et al., 2018); the remainder is on
membranes. We showed previously that exogenously expressed
Rab29 recruits cytosolic LRRK2 onto membranes, where it be-
comes preferentially activated (Purlyte et al., 2018). Given that
cytosolic Rab29 is not bound to GDI, it is possible that it is
available to activate LRRK2 in the cytosol. We thus first tested
whether Rab29 prenylation is needed for LRRK2 activation by
depleting cells of the prenylation precursor geranylgeranyl di-
phosphate by treatment with the HMG-CoA reductase inhibitor
lovastatin. LRRK2 activation was then monitored using an anti-
LRRK2 pS1292 antibody that detects activated LRRK2 protein.
As shown in Fig. 2 (A and B), lovastatin treatment of Myc-
Rab29– and R1441G LRRK2–transfected HEK293T cells strongly
inhibited LRRK2 activation, as monitored by pS1292 antibody
staining, consistent with a previous report (Liu et al., 2018). In
Rab9-containing control reactions, pS1292 LRRK2 levels were
unchanged by lovastatin treatment. Thus, despite the presence
of both free Rab29 and LRRK2 in cytosol, Rab29 activation of
LRRK2 is sensitive to lovastatin treatment. This finding is likely
explained by a requirement for Rab29 prenylation and mem-
brane association; however, lovastatin will also interfere with
prenylation of other proteins, so such a conclusion would be
premature.
LRRK2 phosphorylation of its substrates, Rab8A, Rab10, and
Rab29, also required that these Rab proteins gain membrane
association by C-terminal prenylation, since deletion of their
C-terminal cysteine residues that become prenyl modified
strongly decreased their phosphorylation by LRRK2 kinase, as
monitored using phospho-specific anti-Rab antibodies (Fig. 2 C).
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Important controls included LRRK2 R1441G/D2017A, a mutant
LRRK2 that is defective in kinase activity (Jaleel et al., 2007), and
cell treatment with MLi-2, a LRRK2-specific inhibitor (Scott
et al., 2017) that also abolished Rab protein phosphorylation.
Together, these data suggest that Rabs and LRRK2 only interact
in association with membranes.
Membrane identity is not important for Rab29 activation
of LRRK2
Because membrane association is required for both Rab29-
mediated LRRK2 activation and LRRK2-mediated Rab substrate
phosphorylation, we next tested whether the identity of the
membrane housing the Rab is important. For these experiments,
we first relocalized Rab29 to mitochondria by replacing Rab29’s
two C-terminal cysteines with an amphipathic helix derived
from monoamine oxidase A (Wong and Munro, 2014); this hy-
brid protein will be referred to as mito-Rab29. Upon expression
in HeLa and retinal pigment epithelial (RPE) cells, mito-Rab29
localized predominantly to mitochondria, as monitored by co-
localization withMitoTracker in both HeLa and RPE cells (Figs. 3
and 4 A). Mito-Rab29 did not colocalize with markers of lyso-
somes, the endoplasmic reticulum, early endosomes, or the Golgi
apparatus (Figs. 3 and 4 A). Compared with Golgi-localized Myc-
Rab29 (Purlyte et al., 2018), mito-Rab29 was comparable in its
ability to activate LRRK2, as monitored by the generation of
pS1292 LRRK2 (Fig. 4, B [top row, left panels] and C).
Until now, there was no established Rab29 mutant that was
certain to have lost its nucleotide-binding capacity. To explore
the importance of bound nucleotide on Rab29’s ability to activate
LRRK2 once present on membranes, we took advantage of the
D63A Rab29 mutant. Upon expression as a Myc-tagged protein
in cells, this protein failed to associate withmembranes (Fig. 4 E,
left panels), likely because it cannot interact with the prenyla-
tion machinery that requires nucleotide binding. However, the
protein efficiently associated with membranes in its corre-
sponding mitochondrial targeting form (Fig. 4 E, right panels).
Mito-Rab29 D63A failed to activate R1441G LRRK2 (Fig. 4, B
[right panels] and D), which demonstrates the requirement for
Rab29 nucleotide binding for LRRK2 activation. Importantly,
these data show that the identity of the membrane upon which
Rab29 sits does not influence its ability to activate LRRK2.
Moreover, Rab29 must be both membrane and nucleotide bound
to accomplish LRRK2 activation.
Membrane identity is not important for LRRK2 Rab
substrate phosphorylation
Rab10 colocalizes with R1441G LRRK2 on both perinuclear and
peripheral membrane vesicles (Purlyte et al., 2018). We
Figure 1. Rab29 binds nucleotide weakly and
does not bind GDI in the cytosol. (A–D) Puri-
fied His-Rab5, His-Sumo Rab29, or His-Sumo
Rab29 D63A was loaded with MANT-GDP, and
the release of MANT-GDP fluorescence was fol-
lowed after addition of an excess of unlabeled
GDP. Shown are examples of experiments per-
formed at least three times. A and C are nor-
malized to time zero; B and D are unnormalized,
and a longer time course is shown. (E) The
curves from B and D were fitted to a nonlinear
regression one-phase decay function. Times of
50% dissociation from three experiments per-
formed in duplicate are shown. Error bars rep-
resent SEM. (F) Cytosol collected from 293T cells
transfected with either Myc-Rab8A or Myc-
Rab29 were applied onto an Sephacryl S100
size exclusion column and fractions immuno-
blotted using antibodies to GDI, Myc, or endog-
enous Rab9. (G) HEK392T cells were transfected
with GFP-Rab10 or GFP-Rab29. Cell lysates were
incubated with biotin-labeled geranyl pyro-
phosphate for 4 h at RT. GFP-Rabs were im-
munoprecipitated using beads towhich GFP-binding
nanobody was attached and immunoblotted for
incorporated biotin geranyl pyrophosphate using
streptavidin-IR800 and chicken anti-GFP antibody
for total Rab protein. Shown is an example of an
experiment performed three times. The molecular
mass is shown at left in kilodaltons in this and all
subsequent figures.
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anchored Rab10 onto mitochondria to assess whether it is
still a substrate for LRRK2 phosphorylation when localized
to a nonnative membrane surface (Fig. 5 A). The protein
was specifically localized to mitochondria, as determined
by a Pearson’s correlation coefficient with the mitochon-
drial marker Mitofilin of 0.81 (20 cells measured). Although
GFP-1441G LRRK2 was cytosolic, mito-Rab10 was phos-
phorylated on mitochondria (pRab10 shown in red, Fig. 5
A). Fig. 5 B (top row) shows the levels of pRab10 detected in
cells expressing R1441G LRRK2 and Myc-Rab10 (left col-
umn), mito-Rab10 (center column), or GDP-preferring
mito-Rab10 T23N (right column) in reactions with or
without LRRK2 MLi-2 inhibitor. Even when relocalized to
mitochondria, Rab10 was phosphorylated by LRRK2 to an
extent similar to that seen for WT Myc-Rab10 protein
(Fig. 5, B and D); GDP-preferring Rab10 T23N was not phos-
phorylated by LRRK2 on mitochondria. Thus, LRRK2 can
phosphorylate membrane-associated Rab10 that is capable of
efficient GTP binding, consistent with a recent report on
Rab10 phosphorylation (Liu et al., 2018).
Mito-Rab29 was also phosphorylated by R1441G LRRK2
(Fig. 5, C and E). This suggests that there are no integral mem-
brane effector proteins on Rab10- or Rab29-native membranes
that are needed for Rab phosphorylation by LRRK2. However,
GTP binding is required for LRRK2-Rab substrate recognition.
LRRK2 activated by mito-Rab29 causes local Rab10
accumulation
Because Rab29 can activate and recruit LRRK2 onto the Golgi
complex (Purlyte et al., 2018) and mito-Rab29 can also activate
LRRK2, as determined by immunoblot, we tested whether mito-
Rab29 recruits LRRK2 onto mitochondria. In cells expressing
both R1441G LRRK2 and mito-Rab29, LRRK2 was recruited onto
mitochondria (Fig. 6 A). Quantitation of the colocalization of
mito-Rab29 with R1441G LRRK2 by Pearson’s correlation coef-
ficient confirmed a high level of colocalization for the two pro-
teins (Fig. 7 A).
We expected that LRRK2 recruited and activated on the
surface of mitochondria would then release from that com-
partment to phosphorylate Rab10 on peripheral vesicles. To our
Figure 2. Membrane association enhances
Rab29 activation of pathogenic LRRK2 and
Rab phosphorylation. (A) HEK293T cells were
transfected with R1441G LRRK2 and Myc-Rab29
orMyc-Rab9 and treated with either DMSO or 10
µM lovastatin to inhibit prenylation. Samples
were immunoblotted 24 h later for pS1292
LRRK2, total LRRK2 (UDD3), and Myc. An ∼50-
kD nonspecific band is shown at bottom as a
loading control. (B) Quantitation of A. Error bars
represent SEM from two experiments; P <
0.0001 from two-tailed unpaired t test. (C) HA-
tagged Rab8A, Rab10, and Rab29 were coex-
pressed with FLAG-R1441G LRRK2 (±200 nM
MLi-2, 1.5 h) or FLAG-R1441G/D2017A LRRK2 in
HEK293T cells. Mutant Rab8A(C204S),
Rab10(C199/200S), and Rab29(C202/203S) were
used along with the corresponding WT Rabs.
Samples were immunoblotted for the respective
phosphorylated Rabs, HA, total LRRK2, and
tubulin.
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surprise, when mito-Rab29 recruited LRRK2 onto mitochondria,
pRab10 also relocalized to that compartment (Figs. 6 A and 7 A).
This is surprising, as Rab proteins usually localize to membranes
where they encounter their cognate guanine nucleotide ex-
change factors and are stabilized by subsequent, GTP-dependent
effector binding (Aivazian et al., 2006; Barr, 2013). We hy-
pothesize that GDI can be promiscuous in its delivery of Rabs to
membranes (Barr, 2013); because Rab phosphorylation blocks
interaction with GDI (Steger et al., 2016), a mistakenly delivered
Rab on a mitochondrial surface will become trapped there by a
mechanism that depends on LRRK2 kinase activity.
A prediction of this model is that Rab10 should be retrieved
from mitochondria by GDI upon LRRK2 inhibition with MLi-2.
Control experiments showed that phosphorylation of Rab10
trapped on mitochondria was reversed upon MLi-2 treatment
(Fig. 6 B). Under these conditions, mito-Rab29 and LRRK2 re-
tained their mitochondrial localizations, while total Rab10 re-
verted to a more general perinuclear staining (Fig. 6 A, bottom
two rows). Loss of Rab10 accumulation on mitochondria was
seen in as little as 15 min of inhibitor addition (45 min shown;
Fig. 6 A, bottom panel), supporting the conclusion that this ac-
cumulation is phosphorylation dependent. Thus, when driven
onto mitochondria by Rab29 recruitment and activation, most
LRRK2 traps substrates at that location in an activity-dependent
manner.
Active Rab29 recruits LRRK2
Just as active Rab29 was needed to activate LRRK2 when an-
chored on mitochondrial membranes (Fig. 4, B and D), active
Rab29 was also more capable of recruiting cytosolic R1441G
LRRK2 to that compartment, despite similar levels of protein
expression of the WT and mutant Rab proteins (Figs. 4 E, 6 A,
and 7). Fig. 7 B shows cytosolic localization of LRRK2 upon co-
expression with mito-Rab29 D63A; this is in stark contrast with
the complete relocalization of LRRK2 to mitochondria when
coexpressed with mito-Rab29 WT (Fig. 6 A). Mito-Rab29 (WT)
recruited LRRK2 to mitochondria with a Pearson’s correlation
coefficient of >0.7, while mito-Rab29 D63A and LRRK2 had a
Pearson’s correlation coefficient of 0.4 (Fig. 7 A). Thus, re-
cruitment and activation by Rab29 are linked and both depend
on Rab29’s ability to bind GTP.
We also tested whether LRRK2 recruitment was dependent
on LRRK2 kinase activity. HeLa cells were transfected with
mito-Rab29 and either R1441G LRRK2 or D2017A (kinase-dead)
LRRK2. The Pearson’s correlation coefficient between LRRK2
and mito-Rab29 was unchanged when kinase-dead D2017A
LRRK2 was used or when cells were treated with MLi-2 (Fig. 7
A). This indicates that the Rab29-LRRK2 interaction is insensi-
tive to any conformational changes associated with LRRK2 ac-
tivity changes.
A test of the importance of LRRK2 membrane–cytosol
equilibrium
While trans-Golgi–localized Rab29 activates LRRK2 and recruits
it to the Golgi, most of LRRK2’s primary substrates, Rab8A,
Rab10, and Rab12, show broader distribution across the Golgi
stack and also elsewhere (compare Figs. 6 A and 8 A; Purlyte
et al., 2018). One possibility is that activated LRRK2 releases
from the trans-Golgi to phosphorylate Rabs on nearby
compartments. To explore this, we anchored GFP-LRRK2 on
mitochondria using a mitochondrially anchored, camelid GFP-
nanobody (GBP) that displays an ∼1-nM Kd for GFP (Kubala
et al., 2010).
As shown in Fig. 8 B, mito-GBP was accurately targeted to
mitochondria, as determined by its colocalization with the
protein Mitofilin (Fig. 8 B). In addition, expression of mito-GBP
relocalized GFP-R1441G LRRK2 to the surface of mitochondria
(Pearson’s correlation coefficient = 0.82 for 20 cells); we will
refer to GBP-bound, mitochondrially localized GFP-R1441G
LRRK2 as mito-R1441G LRRK2.
To test whether mito-LRRK2 can phosphorylate Rab10, we
expressed either soluble Myc-GBP or mito-GBP and GFP-R1441G
Figure 3. Mitochondrially targeted Rab29 localizes to mitochondria but
not other compartments. HeLa cells transfected with mito-Rab29 were
stained with MitoTracker 488, anti-Myc, and anti-marker protein antibodies:
LAMP1, Calnexin, EEA1, and Golgi protein p115. Scale bars, 10 µm. All insets
represent a 2.2× magnification.
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LRRK2 with Myc-Rab10 and stained cells for pRab10 in A549
Rab10 knockout cells (Dhekne et al., 2018; Figs. 8, A and C).
When LRRK2 was soluble in cells expressing Myc-GBP, Myc-
Rab10 was seen on perinuclear membranes, and pRab10
accumulated over the mother centriole as a tight spot in the
perinuclear region (Fig. 8 A), as we showed previously (Dhekne
et al., 2018). When mito-GBP was used to anchor LRRK2 on
mitochondria, total Myc-Rab10 accumulated on mitochondria
(Fig. 8 C and quantitation in Fig. 7 A), analogous to what was
observed in cells expressing mito-Rab29 to recruit LRRK2 (Fig. 6
A). Recruitment of Rab10 to mitochondria by mito-LRRK2 was
phosphorylation dependent; kinase-dead mito-D2017A LRRK2
did not recruit significant amounts of Rab10 onto mitochondria
(Figs. 8 D and quantitation in Fig. 7 A).
As an independent test of R1441G LRRK2’s ability to trap
Rab10 on a membrane surface, we also anchored LRRK2 to the
inner leaflet of the plasma membrane using GBP containing the
C-terminal polybasic region that targets K-Ras to the plasma
membrane (Apolloni et al., 2000). We refer to this construct as
PM-LRRK2 (Video 1). PM-LRRK2 relocalized pRab10 and total
Rab10 to the plasma membrane (Fig. 8 E and quantitation in
Fig. 7 A). These data provide further evidence that LRRK2 can
drive the relocalization and accumulation of Rab10 to inappro-
priate membranes via phosphorylation.
Mito-LRRK2 rarely phosphorylates plasma
membrane–targeted Rab10
In these experiments thus far, it was possible for Rab10 to find
LRRK2 on mitochondria or the plasma membrane (via GDI;
compare Figs. 6 A, 8 C, and 9) or cytoplasmic LRRK2 to find Rabs
on their native (or foreign) membrane compartments. Can an
anchored LRRK2 phosphorylate a Rab anchored on another
membrane surface? To study this, we anchored both LRRK2 and
Rab10 on different membranes and monitored subsequent,
LRRK2-mediated Rab10 phosphorylation. For these experi-
ments, Rab10 was anchored onto the plasma membrane by re-
placing its C-terminal cysteines with the polybasic C-terminus
of K-Ras. This construct is referred to here as PM-Rab10.
A significant fraction of PM-Rab10 accurately localized to the
cytoplasmic surface of the plasma membrane of A549 Rab10
Figure 4. Mitochondrially anchored Rab29-
GTP activates LRRK2 as efficiently as Golgi-
associated Rab29. (A) Quantitation of Fig. 3 for
HeLa (left) and RPE cells (right). Pearson’s cor-
relation coefficients calculated from ≥20 cells
are shown. Error bars represent SEM. (B)
HEK293T cells were transfected with LRRK2-
R1441G and either Myc-Rab29 or mito-Rab29,
Rab9, or mito-Rab29 D63A. Samples were im-
munoblotted for pS1292 LRRK2, total LRRK2
(UDD3), and Myc-tag after 24 h of expression. An
∼50-kD nonspecific band is shown at left as a
loading control; a portion of the Ponceau S–
stained filter (∼25 kD) is shown at bottom right
as a loading control. (C) Quantitation of left
panel of B. Amount of active (pS1292) LRRK2
normalized to the amount of total LRRK2 and
Rab29. Error bars represent SEM from four in-
dependent experiments; P > 0.5 from two-tailed
unpaired t test. (D) Quantitation of right panel of
B. Amount of active, pS1292 LRRK2 normalized
to the amount of total LRRK2 and Rab29. Error
bars represent SEM from three experiments with
duplicate samples in each; P values from un-
paired t test: **, P = 0.0017; ****, P < 0.0001.
(E) Immunoblot of membrane proteins and the
equivalent volumes of cytosolic proteins from
HEK293T cells transfected with Myc-Rab29 WT,
Myc-Rab29 D63A, mito-Rab29 WT, or mito-
Rab29 D63A. Blots were probed with anti-Myc
antibodies for Myc-Rab29 or mito-Rab29 anti-
LAMP2 as a membrane marker and anti-tubulin
as a cytosolic marker.
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knockout cells (Fig. 9 B and Video 2). As shown in Fig. 9 A (lanes
1–4, top row), soluble LRRK2 was much more effective at
phosphorylating plasma membrane–anchored Rab10 than
LRRK2 anchored to mitochondria (Fig. 9, A and C). Upon coex-
pression with GFP-R1441G LRRK2 and the soluble control pro-
tein Myc-GBP, PM-Rab10 was phosphorylated and pRab10
localized to the plasma membrane in ∼80% of cells (Fig. 9, B and
E). Upon coexpression with mito-LRRK2 instead of soluble
LRRK2, PM-Rab10 phosphorylation was detected in <20% of
cells (Fig. 9 E). It is possible that a small amount of phosphor-
ylated PM-Rab10 was modified before it reached the plasma
membrane. (Note that this protein could not use GDI for mem-
brane delivery because it is not prenylated.) Collectively, these
data support the conclusion that the ability of LRRK2 to move
between membranes and the cytosol is crucial for efficient Rab
phosphorylation. Rab phosphorylation by immobilized LRRK2
relies on misdelivery of Rab10 to mitochondria; a much lower
percentage of phosphorylation seen with anchored enzyme and
substrate might reflect access via membrane contact sites be-
tween mitochondria and the plasma membrane.
Finally, Fig. 9 A (second row) shows the relative activity of
soluble R1441G LRRK2 (cells expressing Myc-GBP) compared
with mitochondrially anchored R1441G LRRK2 in cells express-
ing mito-GBP. Although total LRRK2 expression levels were
comparable (Fig. 9 A, third row), LRRK2 was more highly au-
tophosphorylated upon mitochondrial membrane anchoring, as
detected by increased anti-pS1292 staining (Fig. 9 A, second
row). Despite higher autophosphorylation in these samples,
Myc-Rab10 substrate phosphorylation was comparable when
catalyzed by either soluble or mitochondrially localized LRRK2
protein (Fig. 9, A [lanes 5–8, top row] and D). It is possible that
membrane anchoring concentrates the kinase in a mode that self
activates without necessarily providing adequate substrate ac-
cess to achieve greater levels of substrate phosphorylation. Fu-
ture work will be needed to explore the basis of LRRK2
activation on membrane surfaces.
Discussion
We have presented here data indicating that LRRK2 is optimally
able to access membrane-associated Rab substrates from a cy-
tosolic pool. A key experiment involved anchoring LRRK2 on
mitochondria and Rab10 at the plasma membrane; soluble or
plasma membrane–anchored LRRK2 had no problem phos-
phorylating WT Rab10, but mitochondrially anchored LRRK2
was much less able to phosphorylate plasma membrane–
anchored Rab10. Mitochondria-associated LRRK2 was never-
theless active; when it was recruited onto mitochondria by
mitochondrially anchored Rab29, it could be activated there for
both auto- and substrate phosphorylation; it was also active
when anchored to mitochondria without exogenous Rab29
Because of its ability to bind and activate pathogenic LRRK2,
Rab29 is an important Rab protein to understand in relation to
the molecular basis of familial Parkinson’s disease (MacLeod
et al., 2013; Beilina et al., 2014; Purlyte et al., 2018). Our data
confirm that Rab29 is an unusual Rab; it binds nucleotide poorly,
appears to be less efficiently prenylated, and is not bound to GDI
in cytosol. Rab29 is most closely related to the proteins Rab32
and Rab38, and there are no obvious sequence differences that
would suggest that it would behave differently from other Rab
Figure 5. Artificially anchored, nucleotide-bound Rab29 and Rab10 are
substrates for pathogenic LRRK2. (A) Light microscopy of A549 Rab10
knockout cells transfected with GFP-R1441G LRRK2 (green) and mito-Rab10
(cyan). pRab10 is shown in red. Scale bar, 10 µm. (B) HEK293T cells trans-
fected with GFP-R1441G LRRK2 and mito-Rab10, Myc-Rab10, or Myc-Rab29
T23N. Lysates were immunoblotted for pRab10, Myc-tag, pS1292 LRRK2, GFP
for total LRRK2, and tubulin. A portion of the Ponceau S–stained filter (∼25
kD) is shown as a loading control. (C) HEK293T cells transfected with R1441G
LRRK2, mito-Rab29, or Myc-Rab29 expressed for 24 h. Lysates were im-
munoblotted for pThr71 Rab29, GFP for total LRRK2, PS1292, and Myc-tag. A
portion of the Ponceau S–stained filter (∼20 kD) is shown as a loading
control. (D) Quantitation of B. Error bars represent SEM from three inde-
pendent experiments. P values calculated from unpaired t test. *, P = 0.02
(two tailed). (E)Quantitation of C. pRab10 or Rab29 levels normalized to total
Rab and p1292/total LRRK2 levels. In D and E, error bars represent SEM from
three independent experiments with duplicate samples. Two-tailed P values
were calculated using an unpaired t test.
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proteins; its structure has not yet been determined. Future
studies of Rab29 must be designed with great care, as canonical
Rab29 mutations such as Q67L (Beilina et al., 2014) do not
function as would be expected (locked in the active conforma-
tion) and should not be used (this protein binds nucleotide more
poorly than WT). Additionally, Rab29 D63A can serve in future
experiments as an appropriate, inactive Rab29 control protein
because it is entirely cytosolic and displays nucleotide binding
that is EDTA insensitive. Note that a small fraction of this
mutant may bind GTP in cells where the GTP concentration
approaches 0.5 mM.
We have shown that Rabs are phosphorylated on membranes
and their prenylation is required for LRRK2 modification, con-
firming and expanding a previous report (Liu et al., 2018). Rab8,
Rab10, and Rab29 all require prenylation-conferred membrane
localization to be phosphorylated by LRRK2, and Rab29 needs to
be membrane localized to activate LRRK2. If Rab29 is not GDI
bound in cytosol, then why is it unable to activate the LRRK2
Figure 6. Mitochondrially anchored Rab29 recruits
pathogenic LRRK2, pRab10, and total Rab10 to mi-
tochondria. (A) Top row: Light microscopy of HeLa cells
transfected with Myc-Rab29 (cyan) and GFP-R1441G
LRRK2 (green); the TGN marker GCC185 is shown in red.
Second row: Light microscopy of HeLa cells transfected
with mito-Rab29 (cyan) and GFP-R1441G LRRK2 (green)
expressed for 24 h. Endogenous pRab10 is shown in red.
Third row: Mito-Rab29 (cyan) and GFP-R1441G LRRK2
(green); endogenous total Rab10 is shown in red. Fourth
row: Mito-Rab29 (cyan) and GFP-R1441G LRRK2 (green).
24 h after transfection, cells were treated with 200 nM
MLi-2 for 45 min, fixed, and stained. Endogenous
pRab10 is shown in red. Fifth row: Mito-Rab29 (cyan)
and GFP-R1441G LRRK2 (green); 24 h after transfection,
cells were treated with 200 nM MLi-2 for 45 min, fixed,
and stained. Endogenous total Rab10 is shown in red.
Reference image of Rab10 without R1441G LRRK2 or
mito-Rab29 expression is shown. Scale bars, 10 µm. (B)
Immunoblot of HEK293T cells expressing mito-Rab29,
1441G LRRK2, and GFP-Rab10 for 24 h. Blot was probed
for pRab10, Myc-tag, GFP, pS1292 LRRK2, and total
LRRK2 (UDD3). MLi-2 treatment was 200 nM at the time
of transfection. A portion of the Ponceau S–stained filter
(∼25 kD) is shown as a loading control.
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that is mostly cytosolic? It is possible that membrane association
confers a local concentration effect and increases the local Rab
concentration on a two-dimensional surface; membrane asso-
ciation may also influence LRRK2 conformation.
For the first time, we have been able to dissociate the im-
portance of Rab nucleotide binding from the process of mem-
brane association. When the Rab10 GDP-preferring mutant
Rab10 T23N is membrane anchored, it is not a substrate for
LRRK2 kinase. Additionally, when Rab29 is membrane anchored
but unable to bind nucleotide (D63Amutant), it does not activate
LRRK2. These data demonstrate that LRRK2 binds Rab29 as a
bona fide Rab effector in cells, and for Rab substrates, GTP
Figure 7. Mitochondrially anchored Rab29-GTP recruits LRRK2. (A) First
four bars: Pearson’s correlation coefficients calculated from three indepen-
dent experiments with ≥40 cells per condition between LRRK2 and Rab29 in
HeLa cells expressing GFP-R1441G LRRK2 or D2017A LRRK2 and either mito-
Rab29 WT or mito-Rab29 D63A after 24 h of expression with or without MLi-
2. MLi-2 treatment was 200 nM at the time of transfection (first four bars). P
values were calculated from unpaired t tests; *, P = 0.03; ***, P = 0.0007 (two
tailed). Second four bars: Pearson’s correlation coefficients calculated from
three independent experiments with ≥20 cells each; total Myc-Rab10 and
mito-R1441G LRRK2 or mito-D2017A LRRK2 (fifth and sixth bars); LRRK2
recruited to mitochondria by mito-Rab29 and pRab10 (seventh bar); PM-
LRRK2 and pRab10 (eighth bar). Error bars represent SEM from three ex-
periments. (B) Light microscopy of a HeLa cell transfected with GFP-R1441G
(green) and mito-Rab29 D63A (cyan). Scale bar, 10 µm.
Figure 8. Mislocalized LRRK2 phosphorylates and traps pRab10. (A)
Light microscopy of an A549 Rab10 knockout cell expressing untagged GBP,
GFP-R1441G LRRK2 (green), and Myc-Rab10 (cyan). pRab10 is shown in red.
(B) Light microscopy of a HeLa cell stained for expressed mito-GBP (magenta)
and “mito” GFP-R1441G LRRK2 (green). Mitofilin staining shown in red. (C)
Light microscopy of a HeLa cell expressing mito-GBP, GFP-R1441G LRRK2
(green), andMyc-Rab10 (red). Mitofilin is shown in cyan. (D) Light microscopy
of a HeLa cell expressing mito-GBP, GFP-D2017A LRRK2 (green), and Myc-
Rab10 (red). Mitofilin is shown in cyan. (E) Light microscopy of a HeLa cell
expressing PM-GBP, GFP-R1441G LRRK2 (green), and Myc-Rab10 (cyan);
pMyc-Rab10 shown in red. The entire Z-stack series of GFP in this cell is
shown in Video 1. Scale bars, 10 µm.
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binding likely orders the switch II domain for efficient recog-
nition by LRRK2.
Our ability to relocalize LRRK2 activation and substrate
phosphorylation to the mitochondrial surface or plasma
membrane inner leaflet demonstrates that the identity of the
membrane supporting this reaction does not matter; there are
no integral membrane Golgi proteins required for Rab29 acti-
vation of LRRK2 kinase. Similarly, Rab10 is also phosphorylated
on mitochondria or the plasma membrane, suggesting that
LRRK2 does not require an activating or binding protein on
endogenous Rab10-containing membranes. We cannot rule out
the possibility that artificially anchored Rab29 or Rab10 recruits
a soluble binding partner to the new compartment that enhances
activation. In vitro reconstitution of Rab29 activation will clarify
this issue. Another remainingmystery is why LRRK2 is activated
upon membrane association, even independent of Rab29
binding.
One perhaps surprising finding in this study is that pRab10
accumulates at the site of LRRK2 activation; when mitochond-
rially anchored Rab29 recruits LRRK2, both total and pRab10
accumulate on the surface of those mitochondria, an abnormal
localization for Rab10. Similarly, plasma membrane–anchored
LRRK2 led to the accumulation of pRab10 at that location. Our
experimental setup traps mislocalized Rabs at the site of phos-
phorylation, because this modification blocks their ability to
interact with GDI protein (Steger et al., 2016). Normally, GDI
delivers GDP-bound Rabs to membranes; they become stabilized
on specific membranes upon encountering their cognate gua-
nine nucleotide exchange factors to convert them to their GTP-
bound forms, enabling subsequent effector binding (Barr, 2013).
When delivered to the wrong membrane, GDP-Rabs are usually
removed by GDI, which recognizes GDP-bound Rab proteins.
When LRRK2 phosphorylates mislocalized Rab proteins, GDI can
no longer bind and relocalize them. Note that some of our assays
used overexpressed proteins, whichmay have a higher tendency
for mislocalization if endogenous effector interactions become
saturated; nevertheless, we did detect relocalization of endoge-
nous Rab10 protein (Fig. 6). Mislocalization of Rab10 to mito-
chondria was due to LRRK2 action, because it was reversed upon
addition of the LRRK2 kinase inhibitor MLi-2. Additionally,
kinase-dead mito-D2017A LRRK2 did not relocalize Rab10 to
mitochondria (Fig. 8), supporting our contention that accumu-
lation is phosphorylation dependent. A yet-to-be-identified
phosphatase must act on pRab10 to permit subsequent Rab10
extraction by GDI. These experiments reveal a significant
level of GDI-Rab mistargeting that has been previously
underappreciated.
The large accumulation of pRab10 and total Rab10 on LRRK2-
containing membrane surfaces suggests that Rab phosphoryla-
tion (and subsequent membrane trapping) could have large
consequences on membrane trafficking events, as shown re-
cently for pRab8A (Rivero-Rı´os et al., 2019). Upon LRRK2
phosphorylation, native Rabs will be unable to be recognized by
GDI protein, thereby interfering with their retrieval and deliv-
ery to donor membranes. Thus, in addition to losing the capacity
to bind effector proteins, LRRK2 Rab phosphorylation is also
predicted to interfere with the GDI retrieval process needed for
optimal Rab GTPase functioning (Steger et al., 2016).
We have shown that LRRK2 associates preferentially with
GTP-bearing Rab29 in cells, apparently independent of LRRK2
kinase activity. This suggests that Rab29 binds to a portion of the
Figure 9. Soluble LRRK2 phosphorylates plasma membrane–targeted
Rab10 more efficiently than mitochondrially anchored LRRK2. (A) Rep-
resentative immunoblot of HeLa cells transfected with either soluble GFP-
R1441G LRRK2 (with soluble Myc-GBP; lanes 1, 2, 5, and 6) or mitochondrially
anchored R1441G-LRRK2 (with mito-GBP; lanes 3, 4, and 7–10) and Myc-
Rab10 (lanes 5–8) or PM-Rab10 (lanes 1–4, 9, and 10). One set of samples
was treated with 200 nM Mli-2 at the time of transfection (lanes 9 and 10).
Blots were probed for pRab10, pS1292 LRRK2, GFP, and Myc-tag. An ∼37-kD
nonspecific band is shown below as a loading control. (B) Light microscopy of
an A549 Rab10 knockout cell expressing GFP-R1441G LRRK2 (green), Myc-
GBP, and PM-Rab10 (cyan). pRab10 shown in red. See also Video 2. Scale bar,
10 µm. (C) Quantitation of data shown in A. Ratio of pMyc-Rab10/total Myc-
Rab10 signal normalized to the amount of total LRRK2 in the sample. Error
bars represent SEM from four independent experiments. ****, P < 0.0001,
unpaired t test two-tailed. (D)Quantitation of A. Ratio of phosphorylated PM-
Rab10/total PM-Rab10 signal normalized to total LRRK2. Error bars represent
SEM from three independent experiments. Unpaired t test two-tailed P value
= ns (E) Quantitation of the percentage of A549 Rab10 knockout cells
transfected with GFP-R1441G LRRK2, Myc- or mito-GBP, and phosphorylated
PM-Rab10 positive. Scored based on presence or absence of phosphorylated
PM-Rab10. Error bars represent SEM from four independent experiments
with >30 cells scored per experiment; **, P = 0.0029, two-tailed unpaired
t test.
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protein that is insensitive to conformational changes associated
with kinase activation. This is a somewhat surprising finding, as
Rab29 is better able to activate hyperactive, pathogenic LRRK2
compared with WT LRRK2 protein. It is possible that under the
conditions of exogenous protein expression, our experiments
were not able to distinguish more subtle affinity differences.
Future work will identify more precisely the Rab29-binding site
on LRRK2 protein.
Finally, if Rab29 recruits LRRK2 to the Golgi, then why would
that not be sufficient to trap pRab10 at the Golgi under normal
conditions? It is important to note that most LRRK2 is not pre-
sent on the Golgi unless Rab29 is overexpressed; Rab29 is nor-
mally a poorly abundant protein in most cultured cells, and
although Rab29 can activate LRRK2 at the Golgi, pathogenic
LRRK2 mutants are nevertheless active in the absence of Rab29.
All of these features indicate that there is still much to be learned
about LRRK2 cell biology and the significance of Rab29 activa-
tion in vivo.
In summary, active LRRK2 is a bona fide Rab29 effector that
recognizes GTP-bound Rab GTPase substrates and phosphor-
ylates them in the context of native and artificial membrane
surfaces. Beyond LRRK2 activation, Rab29’s additional physio-
logical roles remain poorly characterized and warrant further
analysis. At least under conditions of LRRK2 overexpression,
Rab phosphorylation can drive Rab accumulation at the site of
phosphorylation, which could lead to broad trafficking defects.
Greater understanding of the activities of phosphorylated Rabs
will add much to our understanding of the etiology of Parkin-
son’s disease.
Materials and methods
General cloning and plasmids
DNA constructs were amplified in Escherichia coli DH5α and
purified using mini spin columns (Econospin). All sequences
were verified by sequencing (http://www.sequetech.com).
Plasmids encoding His-Sumo-Rab29 (DU50295), HA-Rab 8A
(DU35414), HA-Rab10 (DU44250), and HA-Rab29 (DU5022)
were obtained from the Medical Research Council unit at Dun-
dee, and GBP was obtained from Addgene (49172). Myc-Rab 9Q,
Myc-Rab29, Myc-Rab10, and GFP-binding protein were cloned
into pcDNA 3.1 with an N-terminal 3X-Myc tag between the
BamHI and NotI sites. Rab9 was cloned into pcDNA 3.1 lacking
an N-terminal 3X-Myc tag. Rab29 and Rab10 mutants were
generated by site-directed mutagenesis using Pfu Turbo DNA
polymerase (Agilent Technologies). A mitochondrial targeting
tag was added to the C-termini of Myc-Rab29 (residues 1–201),
Myc-Rab10 (residues 1–198), and Myc-GBP following a 59-GA-
GAGAAA-39 linker between the NotI and ApaI sites. Mito-Rab29
primers were used to amplify Rab29 with the linker (59-ATTATG
GATCCATGGGCAGCCGCGAC-39, 59-ATAATGCGGCCGCACCGG
CGCCAGCACCGGACCAGCTGGAGGACTT-39), or to amplify the
mitochondrial targeting tag (59-ATTATGCGGCCGCCTTCTGGG
AAAGGAACCTGC-39, 59-ATAATGGGCCCTCAAGACCGTGGC
AGGAG-39). The mitochondrial targeting tag sequence was
composed of human monoamine oxygenase A amino acids
490–527. Plasma membrane–targeted Rab10 contained K-Ras
residues 178–188 appended onto the C-terminus of Rab10 resi-
dues 1–198 and GBP using the NotI and ApaI restriction sites in
pcDNA 3.1. Primers to amplify K-ras tail included 59-ATTATG
CGGCCGCCAAAGATGGTAAAAAGAAG-39 and 59-ATAATGGGC
CCTTACATAATTACACACTTTGT-39. C-terminal EGFP-LRRK2-
R1441G was cloned into modified pSLQ1371 with EGFP at the
N-terminus. All constructs are for human genes.
Cell culture
HEK293T, A549, RPE, and HeLa cells (ATCC) were cultured at
37°C and under 5% CO2 in Dulbecco’s modified Eagle’s medium
containing 8% fetal bovine serum, 2 mM Glutamine, and peni-
cillin (100 U/ml)/streptomycin (100 µg/ml). HEK293T and HeLa
cells were transfected with polyethylenimine HCl MAX 4000
(Polysciences). A549 and RPE cells were transfected using lip-
ofectamine 3000 according to the manufacturer’s instructions.
Immunoblotting
SDS-PAGE gels were transferred onto nitrocellulose membranes
using a Bio-Rad Trans-turbo blot system. Membranes were
blocked with either 5% skim milk or 3% BSA in Tris-buffered
saline with Tween-20 for 30 or 60 min at RT, respectively.
Primary antibodies used diluted in blocking buffer were rabbit
anti-GDI (Soldati et al., 1993) 1:1,000, mouse anti-Rab9
(Lombardi et al., 1993) 1:1,000, mouse anti-Myc (9E10 Hybrid-
oma culture supernatant undiluted), 1.2 µg/ml rabbit anti-
pT73Rab10 (230261; Abcam), rabbit anti-pT71 Rab29
(ab241062; Abcam) 1:500, rabbit anti-phospho-Ser1292 LRRK2
(ab203181; Abcam) 1:1,000, chicken anti-GFP (GFP-1010; Aves)
1:1,000, rabbit anti-LRRK2 (ab133518; Abcam), rabbit antitubulin
(11224-1-AP; Proteintech) 1:2,000, and mouse anti-LAMP2 cul-
ture supernatant (H4B4; Developmental Studies Hybridoma
Bank). Primary antibody incubations were either 1 h at RT or
overnight at 4°C. LI-COR secondary antibodies diluted in
blocking buffer used were 680 nm donkey anti-mouse (1:
10,000), 800 nm donkey anti-mouse (1:5,000), 680 nm donkey
anti-rabbit (1:10,000), 800 nmdonkey anti-rabbit (1:5,000), 680
nm donkey anti-chicken (1:10,000), and 800 nm streptavidin (1:
5,000). Secondary antibody incubations were for 1 h at RT. Blots
were imaged using an Odyssey Infrared scanner (LI-COR) and
quantified using ImageJ software.
Membrane fractionation and gel filtration chromatography
HEK293T cells were transfected with Myc-Rab29 or Myc-Rab8
plasmids. 24 h after transfection, cells were chilled, washed,
resuspended in PBS, and then pelleted at 1,000 rpm for 5 min in
a swinging bucket rotor. Cell pellets were resuspended in hy-
potonic buffer (10 mM Hepes, pH 7.4) and incubated on ice for
15 min. Buffer (5×) was added to achieve a final concentration of
1× resuspension buffer (50 mM Hepes, pH 7.4, 150 mM NaCl,
5 mM MgCl2, 0.5 mM DTT, and 100 nM GDP and protease in-
hibitor cocktail; Sigma). The suspension was passed 20 times
through a 25G syringe. Nuclei were pelleted by centrifugation at
1,000 ×g for 5 min at 4°C. The post-nuclear supernatant was
spun at 100,000 ×g for 15 min in a TLA100.2 rotor in a table-top
ultracentrifuge. The resulting cytosolic supernatant was re-
moved, and the membrane pellet was solubilized in
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resuspension buffer containing 0.5% Triton X-100. Protein was
determined by Bradford assay (Bio-Rad). Cytosol was snap fro-
zen in liquid nitrogen and stored at −80°C. Thawed cytosol was
applied onto a 10-ml Sephacryl S100 column (GE Healthcare)
equilibrated in buffer containing 50 mMHepes, pH 7.4, 100 mM
NaCl, 5 mMMgCl2, 0.2 mM DTT, 10 µM GDP, and 10 mM PMSF.
Fractions were collected and weighed for volume, and protein
was determined. Fractions were analyzed by immunoblotting as
described above.
Determination of LRRK2 activation by Rab29
HEK293T cells were transfected with indicated plasmids; 24 h
after transfection, cells were chilled, washed, and resuspended
in PBS. Where applicable, cells were treated with 10 µM lova-
statin (Abcam) at the time of transfection. Cell pellets were re-
suspended in lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl,
5 mMMgCl2, 0.5 mM DTT, and 100 nM GTP, protease inhibitor
cocktail, 0.1 µg/ml microcystin [Calbiochem], 1.15 mM NaF, and
5 mM sodium pyrophosphate). Lysates were incubated at 4°C
with rotation for 15 min and spun at 16,873 relative centrifugal
force in a microcentrifuge for 15 min. Lysate (120 µg) was ana-
lyzed by immunoblot after resolution on a 4–20% gradient gel
(Bio-Rad). Relative activation of LRRK2 was determined using
the ratio of pS1292/total LRRK2, normalizing for Rab29 levels.
Determination of Rab phosphorylation
HEK293T or HeLa cells were transfected with the indicated
plasmids using polyethylenimine HCl MAX 4000; 24 h later,
cells were chilled and washed with PBS. Cells were scraped into
buffer containing 50 mM Tris/HCl, pH 7.5, 1% Triton X-100,
1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 10 mM
β-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 µg/ml
Microcystin-LR, 270 mM sucrose, and protease inhibitor cock-
tail (Sigma). Samples were immunoblotted on 15% gels or 4–20%
precast gradient gels (Bio-Rad).
In vitro prenylation
Cytosol was incubated with 5 µM biotin geranyl pyrophosphate
(Jena Biosciences). Samples were rotated for 4 h at RT and in-
cubated with GFP-binding protein coupled to NHS-activated
Sepharose 4 fast flow resin (GE Healthcare) for 1 h rotating
end over end at 4°C. Resin was washed three times with 1 ml
PBS, eluted with 50 µl 2× SDS sample buffer, and boiled for
5 min. Samples were resolved on a 12% SDS-PAGE gel for im-
munoblot analysis.
Rab purification and MANT-GDP assay
His-Sumo-Rab29 WT and D63A were purified from a 1L culture
of Rosetta II cells induced at OD600 = 0.5–0.7 with 0.4 mM IPTG
(Gold Biotechnology) overnight at 17°C. Cells were resuspended
in 50mM Hepes pH 7.4, 200mM NaCl, 5mM MgCl2, 5mM im-
idazole, 0.5mM DTT, 20 µM GTP, 10% (vol/vol) glycerol, and
protease inhibitors (Sigma) by one passage through an
Emulsiflex-C5 apparatus (Avestin) at 10,000 lb/in2 followed by
centrifugation at 13,000 rpm for 25 min in a FiberLite F15 rotor
(ThermoFisher). Clarified lysates were incubated with 30 µl
cOmplete His-Tag resin (Sigma) for 2 h rotating at 4°C. Resin
was washed three times with 1ml lysis buffer and eluted in
150 mM imidazole-containing lysis buffer. Protein was imme-
diately desalted using a PD MiniTrap G-25 column (GE Health-
care) to remove imidazole. His-tagged Rab5 was used as a
control and purified as described previously (Aivazian et al.,
2006).
For the MANT-GDP binding assay, Rab proteins were loaded
with 25-fold molar excess of MANT-GDP (Invitrogen) in buffer
containing 20mMHepes, 150mMNaCl, 8% glycerol, and 25mM
EDTA in a 25°C water bath for 2 h. The reaction was quenched
with addition of MgCl2 to achieve a final concentration of 40
mM. Proteins were desalted using a 0.5-ml 7K molecular weight
cutoff Zeba spin desalting column (ThermoFisher) into 30 mM
Hepes, pH 7.4, 150 mM NaCl, and 5 mM MgCl2. Samples were
diluted to 1 µM in a final volume of 98 µl of either desalting
buffer or EDTA containing buffer with 30 mM Hepes, pH 7.4,
150 mM NaCl, 5 mM MgCl2, and 20 mM EDTA. Samples were
loaded into a black 94-well plate. Fluorescence was monitored in
a Tecan infinite 200Pro plate reader with excitation at 360 nm
and monitoring 440 nm emission every minute. After an
equilibration period, 2 µl of 10 mM unlabeled GDP was added to
achieve a final concentration of 200 µM. Observed pseudo-first-
order rate constants were extracted from a nonlinear least-
squares fit.
Light microscopy
Cells were plated on glass coverslips and the next day trans-
fected with indicated plasmids. Cells were fixed with 3.5% par-
aformaldehyde in PBS for 15 min, permeabilized for 3 min in
0.1% Triton X-100, and blocked with 1% BSA in PBS. Antibodies
were diluted as follows: mouse anti-Myc (9E10 hybridoma cul-
ture supernatant 1:3), rabbit anti-pRab10 (MJF-R21-22-5, 1 µg/
ml; Abcam), rabbit anti-total Rab10 (MJF-R23 1:500; Abcam),
sheep polyclonal anti-Rab29 (S984D; 2 µg/ml; University of
Dundee), rabbit anti-Mitofilin (NB100, 1:500; Novus), mouse
anti GFP (1:1,000; Neuromab), rabbit anti-calnexin (1:1,000; gift
from Ron Kopito, Stanford University, Palo Alto, CA), mouse anti
EEA1 (1:200; BD Biosciences), rabbit anti-GCC185, and mouse
anti-P115 (ascites). Primary and secondary antibody incubations
were for 1 h at RT. Highly cross-absorbed H+L secondary anti-
bodies (Life Technologies) conjugated to Alexa Fluor 488, 568, or
647 were used at 1:2,000. MitoTracker Green FM was used at
500 nM before fixation for 30min at 37°C. Glass coverslips were
mounted onto slides using mowiol. All images were obtained
using Metamorph software with a spinning disk confocal mi-
croscope (Yokogawa) with an electron-multiplying charge cou-
pled device camera (Andor) and a 100× 1.4-NA oil-immersion
objective at RT. Typical exposure times of 100–300 ms were
used. Nuclei were stained with 0.1 µg/ml DAPI (Sigma). Pear-
son’s correlation coefficients were calculated by analyzing
maximum intensity projection images with CellProfiler software
(Carpenter et al., 2006).
Statistics
Graphs were made using GraphPad Prism 6 software. Error bars
indicate SEM. A Student’s unpaired t test was used to test sig-
nificance. Two-tailed P values <0.05 were considered
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statistically significant. Data distribution was assumed to be
normal, but this was not formally tested.
Online supplemental material
Video 1 shows a confocal Z-series of the HeLa cell shown in Fig. 8
E expressing PM-GBP, GFP-R1441G LRRK2, and Myc-Rab10 to
illustrate the localization of plasma membrane–anchored LRRK2
detected in the GFP channel. Video 2 shows a confocal Z-series of
the A549 Rab10 knockout cell shown in Fig. 9 B expressing GFP-
R1441G LRRK2, Myc-GBP, and PM-Rab10 to illustrate the local-
ization of plasma membrane–anchored Rab10 distribution
detected in the 647-nm channel.
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